We used RNA sequencing to assess the suitability of TGFβ1 treatment of NHLFs as an in vitro model of IPF and examined the effects of the CaSR NAM, NPS2143, on relevant biological pathways. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.